Clinical trials: Abscopal Effect
Metastatic Breast Cancer, Metastatic Colorectal Cancer
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
The proposed theory is based on combination of radiation therapy with usual targeted therapies capable of ADCC (Antibody-Dependant Cell Cytotoxicity).
- Conditions
- Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
- Trial name
- IRAM (NCT03323424)
- Testing
- Systemic treatment + Stereotactic Body Radio-Therapy (SBRT), Systemic treatment
- Where
- 6 sites in France
- Sponsor
- Institut de Cancérologie de la Loire
Non-Small-Cell Lung Cancer Stage IV
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC
This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC) with previously failed after…
- Trial name
- NCT04238169
- Testing
- Bevacizumab, Toripalimab, SBRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinqiao Hospital of Chongqing
Thymic Epithelial Tumor
Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Peginterferon alfa-2b is safe, effective in the…
- Trial name
- NCT04517539
- Testing
- rhGM-CSF，Peginterferon alfa-b2，radiation
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shanghai Cancer Hospital, China
Thymoma
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of patients with advanced thymic…
- Trial name
- NCT05407649
- Testing
- Radiotherapy Combined with GM-CSF
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
Solitary Bone Plasmacytoma
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
This study is being done to evaluate whether the combination of immune therapy and radiation therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the abnormal cells in the bone marrow and perhaps…
- Trial name
- NCT03196401
- Testing
- Durvalumab, Radiation therapy
- Where
- 6 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC Stage IV Without EGFR/ALK Mutation
Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases
This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and…
- Trial name
- NCT06953843
- Testing
- Benmelstobart combined with chemotherapy, Benmelstobart combined with Bevacizumab and chemotherapy
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Xinqiao Hospital of Chongqing
Carcinoma, Unspecified Site
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)
- Trial name
- NCT03396471
- Testing
- Pembrolizumab, External Beam Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Hoosier Cancer Research Network
Carcinoma, Renal Cell
Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.
Tyrosine kinase inhibitors (TKIs) are often used in the standard treatment for patients with metastasized renal cell carcinoma. In addition to their ability to specifically inhibit tumor growth, TKIs also interfere with the…
- Trial name
- NCT02334709
- Testing
- Stereotactic body radiotherapy
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University Hospital, Ghent
Colorectal Cancer, Metastatic Colorectal Cancer
Abscopal Effect for Metastatic Colorectal Cancer
Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin
- Trial name
- NCT02535988
- Testing
- Radiation therapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Colorectal Cancer (CRC), Gastric Cancer (GC)
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
The goal of this single-arm, open-label, prospective clinical trial is to evaluate the safety, feasibility, and preliminary antitumor activity of intratumoral oncolytic virus (H101, recombinant human type 5 adenovirus) combined…
- Conditions
- Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07850882
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jie Yuan，MD
Breast Cancer, Metastatic Breast Cancer
Phase II Study for Solid Metastatic Tumors
1. To induce immunity-mediated tumor response outside the radiation field (abscopal effect) after chemo-radiation of a metastatic site in metastatic breast cancer patients. 2. To monitor the induction of a T cell response. 3.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Solid Tumor
- Trial name
- NCT02474186
- Testing
- Radiation therapy, Xeloda, paclitaxel
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Non-small Cell Lung Cancer, NSCLC
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy.
- Trial name
- NCT04245514
- Testing
- Durvalumab, Radiotherapy
- Where
- 13 sites in Germany, Switzerland
- Volunteers
- 90 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer Metastatic
Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine whether radiation combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe and effective for patients with metastatic non-small cell lung cancer.
- Trial name
- NCT03113851
- Testing
- Radiotherapy, rhGM-CSF
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response.
- Trial name
- NCT06327178
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Carcinoma, Non-Small-Cell Lung
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of stage IV…
- Trial name
- NCT02623595
- Testing
- Stereotactic body radiotherapy, rhGM-CSF
- Where
- China
- Sponsor
- Wuhan University
Colorectal Liver Metastases
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
This pilot phase I trial aims to investigate the efficacy and safety of high- and low-dose radiotherapy combined with programmed cell death-1 (PD-1) inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)…
- Trial name
- HaRyPOT (NCT06045286)
- Testing
- Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Renal Cell Cancer Metastatic
Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma
The goal of this multicenter observational study is to elucidate the clinical and immunological characteristics of the abscopal effect in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitors…
- Trial name
- AURICRE (NCT07240610)
- Where
- Japan
- Volunteers
- 145 people
- Sponsor
- Zhe Chen